A Phase 3 Randomized Double-blind Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

Brief description of study

You are being asked to participate in this research study because you have endometrial cancer. This study is being done to find out if an investigational drug called dostarlimab (also known as TSR-042) an immunotherapy drug in combination with chemotherapy (carboplatin and paclitaxel), can help delay worsening of cancer among patients.

Clinical Study Identifier: s19-00354
ClinicalTrials.gov Identifier: NCT03981796

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.